DTx opportunity for pharmaceutical companies

Pharma companies are accelerating their incorporation of digital tools across all aspects of their business with Digital Therapeutics (DTx) being an element of this digital transformation. However, what DTx means in practice for Pharma companies is still primarily pilots as companies grapple to see how to monetize DTx in a traditional pharma business. How can pharma companies define the ROI of integrating DTx in their offerings? So far, most pharma-DTx collaborations have been companion-style DTx as opposed to standalone therapies, but will this change in the next few years? From an organizational perspective, what are the key changes pharma needs to do to successfully integrate DTx in their business model? Join this informal conversation with other thought leaders to discuss the current and future opportunities for pharma in DTx.